BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17. “We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseases,” said Da ...